|
EVIDENCE
WATCH
A review and assessment of recent clinical trial data
Neoadjuvant lapatinib
Joseph
Ragaz, MD, FRCPC
DECREASE IN TUMORIGENIC BREAST CANCER STEM CELLS IN PRIMARY
BREAST CANCERS WITH NEOADJUVANT LAPATINIB. SABCS 2007, ABSTRACT
82.
Adjuvant chemotherapy in high-risk
breast cancer
Sunil
Verma, MD, MSEd, FRCP and Danny Robson, MD, FRCPC
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL SUPPORT VERSUS
STANDARD-DOSE CHEMOTHERAPY: META-ANALYSIS OF INDIVIDUAL PATIENT
DATA FROM 15 RANDOMIZED ADJUVANT BREAST CANCER TRIALS. SABCS
2007, ABSTRACT 11.
EXTENDED FOLLOW-UP AND ANALYSIS BY AGE
OF THE US ONCOLOGY ADJUVANT TRIAL 9735: DOCETAXEL/CYCLOPHOSPHAMIDE
IS ASSOCIATED WITH AN OVERALL SURVIVAL BENEFIT COMPARED TO
DOXORUBICIN/CYCLOPHOSPHAMIDE AND IS WELL-TOLERATED IN WOMEN
65 OR OLDER.SABCS 2007, ABSTRACT 12.
Prognostic molecular testing in breast
cancer
Debjani
Grenier, MD, FRCPC
PROGNOSTIC AND PREDICTIVE VALUE OF THE 21-GENE RECURRENCE
SCORE ASSAY IN POSTMENOPAUSAL, NODE-POSITIVE, ER-POSITIVE
BREAST CANCER (S8814, INT0100). SABCS 2007, ABSTRACT 10.
Multiple myeloma
Kevin
W. Song, MD, FRCPC
MELPHALAN-PREDNISONE-THALIDOMIDE (MP-T) DEMONSTRATES A SIGNIFICANT
SURVIVAL ADVANTAGE IN ELDERLY PATIENTS >/=75 YEARS WITH
MULTIPLE MYELOMA COMPARED WITH MELPHALAN-PREDNISONE (MP) IN
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, IFM
01/01. ASH 2007, ABSTRACT 795.
Acute lymphoblastic leukemia
Stephen
Couban, MD, FRCPC
IMPROVED EARLY EVENT FREE SURVIVAL (EFS) IN CHILDREN WITH
PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC
LEUKEMIA (ALL) WITH INTENSIVE IMATINIB IN COMBINATION WITH
HIGH DOSE CHEMOTHERAPY: CHILDREN’S ONCOLOGY GROUP (COG)
STUDY AALL0031. ASH 2007, ABSTRACT 4.
|
